ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
- PMID: 29074100
- DOI: 10.1016/S1470-2045(17)30708-8
ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
Erratum in
-
Correction to Lancet Oncol 2017; 18: 1555-56.Lancet Oncol. 2017 Dec;18(12):e711. doi: 10.1016/S1470-2045(17)30867-7. Lancet Oncol. 2017. PMID: 29208434 No abstract available.
Comment on
-
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
